RMC No. 4-2019: VAT Exemption for FDA-Listed Diabetes, High-Cholesterol, and Hypertension Drugs

RMC No. 4-2019 publishes the FDA list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs for pharmacy and healthcare VAT compliance. Pharmacies, hospitals, drug distributors, and VAT-registered sellers of medicine must treat the FDA-identified drugs for diabetes, high cholesterol, and hypertension as VAT-exempt once covered by the published FDA list. RMC No. 4-2019 matters because the […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]